The Cell Core C is the keystone of the FSHD-Wellstone research activities and will be responsible for thedevelopment and maintenance of reagents for its investigators and the FSHD research community at-large.Every project in this proposal will draw from its resources. A FSHD tissue bank (Aim 1) will be establishedfrom patients and first-degree family members specifically recruited, screened and enrolled to provide highquality and highly relevant biological specimens. Open muscle biopsies of FSHD muscle and control musclewill be obtained from 3 participating sites: Johns Hopkins, University of Utah and University of Sao Paulo,and distributed to multiple institutions for studies proposed. The Cell and Molecular Lab (Aim 2) of the Corewill be located at BBRI and will perform several functions including the establishment of primary andsecondary cultures and selected immortalized clonal lines from biopsy materials of FSHD subjects andprimary relatives. Additionally, evaluation of biochemical, cell biological, proteomic and molecular dataobtained from the relevant cell cultures and immortalized cell lines will be made available to the FSHDscientific community through the establishment of a national resource FSHD muscle cell repository. AnFSHD myoblast cell repository (Aim 3) will be established through collaboration with Genzyme/Myosix andan FSHD lymphocyte repository will be established with The Coriell Institute. Finally the BioinformaticsSupport Group (Aim 4) will have a large role in this Center, serving all projects as well as individual aspectsof the Cell Core. The Bioinformatics Support Group will set-up and maintain a portal for standardizing,managing and sharing data between collaborating laboratories in the Center, and for making data publiclyavailable as a companion to the public myoblast cell repository. It will also perform the computationalanalysis and modeling of the data produced by Cell Core C, including transcriptomic data, proteomics data,and data from cell-based assays. The Bioinformatics component will use both statistical and machinelearningapproaches to identify FSHD biomarkers from across the different data modalities, and will performintegrative analysis, with the goals of understanding the pathways that are disrupted in FSHD and identifyingand assessing potential therapeutic targets.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54HD060848-01
Application #
7536207
Study Section
Special Emphasis Panel (ZAR1-KM-J (M1))
Project Start
2008-09-10
Project End
2013-08-31
Budget Start
2008-09-10
Budget End
2009-08-31
Support Year
1
Fiscal Year
2008
Total Cost
$466,499
Indirect Cost
Name
Boston Biomedical Research Institute
Department
Type
DUNS #
058893371
City
Watertown
State
MA
Country
United States
Zip Code
02472
Leung, Doris G; Wang, Xin; Barker, Peter B et al. (2018) Multivoxel proton magnetic resonance spectroscopy in facioscapulohumeral muscular dystrophy. Muscle Nerve 57:958-963
Wallace, Lindsay M; Saad, Nizar Y; Pyne, Nettie K et al. (2018) Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. Mol Ther Methods Clin Dev 8:121-130
Giesige, Carlee R; Wallace, Lindsay M; Heller, Kristin N et al. (2018) AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. JCI Insight 3:
Chagarlamudi, Hema; Corbett, Alastair; Stoll, Marion et al. (2017) Bone health in facioscapulohumeral muscular dystrophy: A cross-sectional study. Muscle Nerve 56:1108-1113
Eichinger, Katy; Heatwole, Chad; Heininger, Susanne et al. (2017) Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy. Muscle Nerve 55:333-337
Ansseau, Eugénie; Vanderplanck, Céline; Wauters, Armelle et al. (2017) Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD). Genes (Basel) 8:
Shaw, Natalie D; Brand, Harrison; Kupchinsky, Zachary A et al. (2017) SMCHD1 mutations associated with a rare muscular dystrophy can also cause isolated arhinia and Bosma arhinia microphthalmia syndrome. Nat Genet 49:238-248
Widrick, Jeffrey J; Alexander, Matthew S; Sanchez, Benjamin et al. (2016) Muscle dysfunction in a zebrafish model of Duchenne muscular dystrophy. Physiol Genomics 48:850-860
Chen, Jennifer Cj; King, Oliver D; Zhang, Yuanfan et al. (2016) Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics. Mol Ther 24:1405-11
Ansseau, Eugénie; Eidahl, Jocelyn O; Lancelot, Céline et al. (2016) Homologous Transcription Factors DUX4 and DUX4c Associate with Cytoplasmic Proteins during Muscle Differentiation. PLoS One 11:e0146893

Showing the most recent 10 out of 34 publications